how to use crypto Top Knowledge

SpaceX is valued at about $350 billion due to internal stock sales. According to an email sent to employees seen by the media, SpaceX and its investors have agreed to acquire the company's common stock of up to $1.25 billion at a price of $185 per share. This transaction values the rocket and satellite manufacturer owned by elon musk at about $350 billion. The memo said that the price of $185 per share was much higher than the valuation of $112 less than three months ago. The memorandum was further confirmed by insiders. According to the memo, only SpaceX offered to buy up to $500 million in common stock.Policy combination boosts confidence, and public offering: China's assets will usher in a further increase in valuation. On December 9, the Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting to analyze and study the economic work in 2025. A number of public offerings said that the meeting sent a very positive signal. At present, the economy is resilient, the investor structure is constantly optimized, and the market activity continues to increase. China assets may have an opportunity to raise their valuations again. From the perspective of funds, Jing Shun Great Wall Fund analyzed that the current A-share market is in the most active stage since 2015, and there are many potential bulls in the market. Policy expectations are expected to drive incremental funds into the market, forming a resonance between emotions and funds. (SSE)Russian Foreign Ministry Spokesperson Zacharova: The Russian Federation keeps in touch with all political forces in Syria. The Russian Federation is holding an operational headquarters meeting to discuss the security of Russians and Russian facilities in Syria.

Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Zhejiang Alibaba Cloud has invested in Sealos, and Tianyancha App shows that recently, Sealos affiliated company Zhuhai Huanjie Cloud Computing Co., Ltd. has undergone industrial and commercial changes, adding Zhejiang Alibaba Cloud Computing Co., Ltd. as a shareholder, and the registered capital has increased from about 2.679 million RMB to about 3.349 million RMB. Zhuhai Huanjie Cloud Computing Co., Ltd. was established in March 2022, and its legal representative is Fang Haitao. Its business scope includes computer software and hardware and auxiliary equipment wholesale, computer software and hardware and auxiliary equipment retail, cloud computing equipment technical services, etc. Now it is jointly held by Fang Haitao, Hangzhou Fanjie Enterprise Management Partnership (Limited Partnership) and the above-mentioned new shareholders. Official website shows that the company focuses on developing and providing cloud native ecological products and services.Expert: Central enterprises will continue to recruit in A-shares. On the evening of December 9, Huada Jiutian, a domestic EDA leader, announced that China Electronic Information Industry Group Co., Ltd. will become the actual controller of the company. So far, the number of A-share listed companies "incorporated" by central enterprises reached 10 in 2024. The end of 2024 is an important node for central enterprises to optimize the layout of listed platforms. The Work Plan for Improving the Quality of Listed Companies Controlled by Central Enterprises previously issued by the State-owned Assets Supervision and Administration Commission of the State Council made it clear that the adjustment and revitalization of the listing platform should be basically completed by the end of 2024, and it is supported to revitalize through absorption and merger, asset restructuring and cross-market operation, or to withdraw through free transfer and equity transfer, so as to further focus on the main business and advantageous areas. Looking forward to the next layout rhythm of central enterprises in the capital market, many experts interviewed by reporters believe that the pace of "recruiting" of central enterprises in A shares will continue. In the coming period, the cases of central enterprises strengthening their main business through capital operation and giving play to their strategic support and industrial leading functions will be on the rise. (shanghai securities news)

Market information: Honda will terminate its autonomous driving partnership with General Motors.Xie Yunliang, macro chief analyst of Cinda Securities, said that historically, the establishment of a "moderately loose" policy orientation needs to meet two major conditions, namely, the domestic pressure to stabilize prices is high and the foreign Federal Reserve is in a loose cycle. At present, it is judged that both situations may exist next year.Huaxi Securities: Maintaining the "Buy" rating of this century is expected to outperform the industry. Huaxi Securities Research Report pointed out that the Spring Festival is the most rigid peak season for liquor demand in a year, and it is also the key node for liquor companies to complete sales and promote marketing. It is expected that the demand for business banquets, corporate annual meetings, family gatherings, gifts from relatives and friends will be stronger, and the marketing of the industry will be improved after the Spring Festival. This century (603369.SH In the short and medium term, in order to seize the window period of intensive cultivation in the province, it is relatively more important for the company to improve its market share and expand its market coverage. It is considered that under the trend of intensified competition in the industry, it is not excluded that the company can maintain its current investment and even increase its investment in a targeted manner, so it is relatively cautious to calculate the profit elasticity. At present, the industry has entered a period of slowdown and the company will be more pragmatic in setting goals. However, the company's own advantages are still accumulating and it is expected to outperform the industry relatively. Maintain the "buy" rating.